The DPP-4 inhibitor prolongs the action of incretin hormones by inhibition of their breakdown and improves glycemic control through incretin hormone-induced decrease in glucagon levels and increase in endogenous insulin secretion in patients with type 2 diabetes. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.